Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics. (1st April 2021)

• Record Type: Journal Article
• Authors: Chen, Yu; Liu, Xiaoqing; Guo, Yanxia; Wang, Jianchuan; Zhang, Dingxiao; Mei, Yang; Shi, Junfeng; Tan, Wenzhi; Zheng, Jin Hai
• Is Part Of: Acta biomaterialia. Volume 124(2021)
• Page Start: 72
• Page End: 87
• Publication Date: 2021-04-01
• Subjects: Attenuated bacteria -- Genetic engineering -- Cancer immunotherapies -- Anticancer payloads -- Drug delivery systems; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2021.02.006
• Languages: English
• ISSNs: 1742-7061

Abstract

Abstract: Drug delivery systems based on genetically engineered oncolytic bacteria have properties that cannot be achieved by traditional therapeutic interventions. Thus, they have attracted considerable attention in cancer therapies. Attenuated bacteria can specifically target and actively penetrate tumor tissues and play an important role in cancer suppression as the "factories" of diverse anticancer drugs. Over the past decades, several bacterial strains including Salmonella and Clostridium have been shown to effectively retard tumor growth and metastasis, and thus improve survival in preclinical models or clinical cases. In this review, we summarize the unique properties of oncolytic bacteria and their anticancer mechanisms and highlight the particular advantages compared with traditional strategies. With the current research progress, we demonstrate the potential value of oncolytic bacteria-based drug delivery systems for clinical applications. In addition, we discuss novel strategies of cancer therapies integrating oncolytic bacteria, which will provide hope to further improve and standardize the current regimens in the near future. Graphical abstract: Image, graphical abstract